Retatrutide
aka Retatrutide (LY3437943 — GLP-1/GIP/Glucagon triple agonist)
Mechanism
Retatrutide (Eli Lilly code LY3437943) is an investigational triple-receptor agonist simultaneously targeting GLP-1, GIP, and glucagon receptors. It is research-only and NOT FDA-approved as of April 2026; the Phase 3 TRIUMPH program is ongoing with anticipated NDA filing in 2026. Published Phase 2 data showed roughly 24% mean body weight loss at 48 weeks on 12 mg weekly (Jastreboff, NEJM 2023).
Identification
| CAS number | 2381089-83-2 |
|---|---|
| Molecular formula | C221H342N46O68 |
| Sequence | YXQGTFTSDYSIXLDKKAQXAFIEYLLEGGPSSGAPPPS |
| Typical dose | 0.5–12 mg once weekly subcutaneous (Phase 2 titration; 2–8 mg most studied maintenance range) |
| Half-life | ~6 days |
Vendors selling Retatrutide
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Peptide Partners | 48 mg | $273.00 | — | 99 |
| Crush Research | 20 mg | $76.33 | — | 95 |
| Crush Research | 50 mg | $116.33 | — | 95 |
| Crush Research | 10 mg | $129.00 | — | 95 |
| Crush Research | 15 mg | $199.00 | — | 95 |
| Crush Research | 30 mg | $249.00 | — | 95 |
| Orbitrex Peptides | 10 mg | $79.99 | — | 95 |
| Orbitrex Peptides | 20 mg | $129.99 | — | 95 |
| Orbitrex Peptides | 30 mg | $210.00 | — | 95 |
| Orbitrex Peptides | 36 mg | $219.99 | — | 95 |
| Profound Aminos | 5 mg | $69.00 | — | 95 |
| Prime Peptides | 10 mg | $120.00 | — | 95 |
| Prime Peptides | 30 mg | $120.00 | — | 95 |
| Prime Peptides | 60 mg | $120.00 | — | 95 |
| Amino Club | 30 mg | $179.99 | — | 93 |
| Skye Peptides | 12 mg | $90.00 | — | 90 |
| Qihang Peptide | — | — | — | 87 |
| Peptidegurus | 10 mg | — | — | 84 |
| Peptidegurus | 20 mg | — | — | 84 |
| Peptidegurus | 30 mg | — | — | 84 |
| Reta Peptide | — | — | — | 83 |
| Cocer Peptides | 10 mg | $200.00 | — | 82 |
| Cocer Peptides | 30 mg | $430.00 | — | 82 |
| Cocer Peptides | 40 mg | $480.00 | — | 82 |
| Cocer Peptides | 50 mg | $580.00 | — | 82 |
| Blank Peptides | 10 mg | $130.00 | — | 81 |
| Blank Peptides | 20 mg | $130.00 | — | 81 |
| Blank Peptides | 30 mg | $130.00 | — | 81 |
| Crystal Peptides | 10 mg | $99.00 | — | 66 |
| Crystal Peptides | 20 mg | $159.99 | — | 66 |
| Crystal Peptides | 30 mg | $199.00 | — | 66 |
| Peptiatlas | — | — | — | 51 |
| Peptiatlas | — | — | — | 51 |
| Taishijie | — | — | — | 51 |
| Taikangbio | — | — | — | 50 |
| Zjpeptix | — | — | — | 50 |
| Hkuppeptide | 10 mg | $10.00 | — | 50 |
| Hkuppeptide | — | $10.00 | — | 50 |
| Hkuppeptide | 10 mg | $10.00 | — | 50 |
| Hkuppeptide | 5 mg | $10.00 | — | 50 |
| Hkuppeptide | 15 mg | $10.00 | — | 50 |
| Hkuppeptide | 10 mg | $10.00 | — | 50 |
| MEI-PEPETIDE | 5 mg | $120.00 | — | 48 |
| DongCheng Peptide | — | — | — | 46 |
| Mandy | 5 mg | $45.00 | — | 43 |
| HongDa Peptide | — | $77.00 | — | 43 |
| zztai Peptide Ltd | — | — | — | 43 |
| MJT peptides | 5 mg | $70.00 | — | 39 |
| HK Peptide Ltd (hk peptides) | 10 mg | $145.00 | — | 37 |
| Alpha Peptides | — | — | — | — |
| Apollo Peptide Sciences | 10 mg | $135.99 | — | — |
| Apollo Peptide Sciences | 15 mg | $189.99 | — | — |
| Apollo Peptide Sciences | 30 mg | $349.99 | — | — |
| Cernum Biosciences | 5 mg | $94.99 | — | — |
| Cernum Biosciences | 10 mg | $94.99 | — | — |
| Cernum Biosciences | 15 mg | $94.99 | — | — |
| Cernum Biosciences | 20 mg | $94.99 | — | — |
| NG Peptide | 10 mg | $42.00 | — | — |
| Strate Labs | 60 mg | $299.00 | — | — |
| Bulk Peptides | 20 mg | $600.00 | — | — |
| Bulk Peptides | 10 mg | $380.00 | — | — |
| Polaris Peptides | 10 mg | $120.00 | — | — |
| Polaris Peptides | 35 mg | $320.00 | — | — |
| Polaris Peptides | 5 mg | $70.00 | — | — |
| Polaris Peptides | 15 mg | $160.00 | — | — |
Research
Diabetes mellitus is associated with cognitive impairment and neurodegenerative changes, partly through hyperglycaemia-driven neuroinflammation and disrupted neuronal signalling.
source →Introduction It has been reported that glucagon-like peptide-1 (GLP-1) agonists or dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists exert beneficial effects on blood pressure and lipid profile.
source →Background Retatrutide is a GIP, GLP-1, and glucagon triple hormone receptor agonist, under clinical development for type 2 diabetes, obesity, and related complications.
source →Retatrutide is a novel triple agonist that targets the glucagon receptor (GCGR), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon-like peptide-1 receptor (GLP-1R).
source →Background and hypothesis Retatrutide is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors that reduced weight and hemoglobin A1c (HbA1c) in individuals with obesity and type 2 diabetes (T2D).
source →Context In phase 2 trials, retatrutide reduced body weight, hemoglobin A1c, and improved the lipid profiles of participants living with obesity, with and without T2D. Objective Assess plasma metabolome and lipidome changes associated with retatrutide treatment.
source →Retatrutide is a first-in-class, unimolecular triple hormone receptor agonist targeting glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors.
source →BACKGROUND: Retatrutide, a novel GIP, GLP-1, and glucagon receptor triple agonist, exhibits unprecedented weight-reducing efficacy in clinical trials, yet the molecular basis of its systemic metabolic benefits remains unclear.
source →Adolescent obesity is an escalating global health concern associated with increased risks of cardiovascular disease, type 2 diabetes mellitus, and long-term metabolic complications.
source →Objective/methods Our aim was to evaluate the efficacy of the triple glucagon, GIP, and GLP-1 receptor agonist retatrutide in diet-induced obese MASH mouse and hamster models, two preclinical models that we routinely use for assessing new therapies targeting obesity.
source →The purpose of this study is to evaluate the efficacy and safety of retatrutide compared with placebo for body weight reduction. Participation in the study will last about 65 weeks and may include about 18 visits.
source →The main purpose of the SYNERGY-OUTCOMES study is to find out whether retatrutide and tirzepatide can prevent major adverse liver outcomes (MALO) in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD).
source →The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutid…
source →The main purpose of this study is to evaluate the efficacy and safety of retatrutide in relieving chronic low back pain in participants who have obesity or overweight. Participation in the study will last about 80 weeks.
source →Phase 2 RCT: retatrutide reduced liver fat in metabolic-dysfunction-associated steatotic liver disease (MASLD).
source →Network meta-analysis comparing GLP-1 receptor agonists and polyagonists (including retatrutide) for weight loss.
source →Phase 2 RCT: the triple GIP/GLP-1/glucagon agonist retatrutide produced large, dose-dependent weight loss (~24% at the top dose) over 48 weeks.
source →The main purpose of this study is to assess the amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to healthy participants. The study will last up to 5 weeks, excluding screening.
source →This is a study of LY3437943 in participants who have obesity or are overweight. The main purpose is to learn more about how LY3437943 affects body weight loss. The study will last about 18 months and may include up to 18 visits.
source →The main purpose of this study is to learn about the side effects of LY3437943 when given to participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body.
source →This study is being conducted to determine the side effects related to LY3437943 given as a single injection under the skin to healthy participants. Blood tests will be performed to check how much LY3437943 gets into the bloodstream and how long the body takes to get rid of it.
source →